Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion

Clinical Cancer Research

Volumn 7, Issue 4, 2001, Pages 784-790

  Lans, Titia E ^a   Bartlett, David L ^a   Libutti, Steven K ^a   Gnant, Michael F X ^a   Liewehr, David J ^a   Venzon, David J ^a   Turner, Ewa M ^a   Alexander, H Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; IODINE 131; MELPHALAN; RECOMBINANT TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; GASTRODUODENAL ARTERY; HEART RATE; HUMAN; INFERIOR CAVA VEIN; ISOTOPE LABELING; LIVER PERFUSION; MALE; MEAN ARTERIAL PRESSURE; PARAMETER; PRIORITY JOURNAL; PULMONARY ARTERY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, ALKYLATING; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; LIVER; MALE; MELPHALAN; MIDDLE AGED; PERFUSION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034896632     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. An endotoxin-induced serum factor that causes necrosis of tumors
2. Tumor necrosis factor: Basic principles and clinical application in systemic and regional cancer treatment
3. Shock and tissue injury induced by recombinant human cachectin
4. Passive immunization against cachectin/tumor necrosis factor protects mice from the lethal effect of endotoxin
5. High-dose recombinant tumor necrosis factor α in combination with interferon γ and melphalan in isolation perfusion of the limbs for melanoma and sarcoma
6. Isolated limb perfusion in primary and recurrent melanoma: Indications and results
7. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas
8. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver
9. A prospective randomized trial of therapeutic isolated limb perfusion (ILP) comparing melphalan (M) versus melphalan, tumor necrosis factor (TNF), and interferon-γ (IFN): An initial report
10. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion (ILP) with high-dose TNF, interferon-γ, and melphalan
11. Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion
12. Isolated hepatic perfusion: A potentially effective treatment for patients with metastatic or primary cancers confined to the liver
13. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia tumour necrosis factor a and melphalan
14. First experience and technical aspects of isolated liver perfusion for extensive liver metastasis
15. National Cancer Institute experience with regional therapy for unresectable primary and metastatic cancer of the liver or peritoneal cavity
16. Estimating the dimension of a model
17. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies
18. Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor a and melphalan on the human fibrinolytic system
19. Effects of hyperthermic isolated limb perfusion with tumor necrosis factor-α and melphalan on pulmonary function assessments
20. Systemic and hemodynamic effects of recombinant tumor necrosis factor α in isolation perfusion of the limbs
21. Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor α (TNF-α) and melphalan in patients with colorectal liver metastases
22. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity
23. Increased plasma levels of Interleukin-6 in sepsis
24. Interleukin-8 sepsis: Relation to shock and inflammatory mediators
25. Two types of septic shock classified by the plasma levels of cytokines and endotoxin
26. Plasma cytokine determinations in emergency department patients as a predictor of bacteremia and infectious disease severity
27. Circulating interleukin-8 concentrations in patients with multiple organ failure of septic and nonseptic origin
28. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma
29. The veno-occlusive disease of the liver
30. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-α challenge in mice
31. Anti-interleukin-8 monoclonal antibody reduces free radical production and improves hemodynamics and survival rate in endotoxic shock in rabbits